脾脏
实验性自身免疫性脑脊髓炎
医学
人口
免疫学
多发性硬化
免疫系统
环境卫生
作者
Ako Ishihara,Jun Ishihara,Elyse A. Watkins,Andrew C Tremain,Mindy Nguyen,Ani Solanki,Kiyomitsu Katsumata,Aslan Mansurov,Erica Budina,Aaron T. Alpar,Peyman Hosseinchi,Lea Maillat,Joseph W. Reda,Takahiro Kageyama,Melody A. Swartz,Eiji Yuba,Jeffrey A. Hubbell
标识
DOI:10.1038/s41551-020-00627-3
摘要
Interleukin-4 (IL-4) suppresses the development of multiple sclerosis in a murine model of experimental autoimmune encephalomyelitis (EAE). Here, we show that, in mice with EAE, the accumulation and persistence in the lymph nodes and spleen of a systemically administered serum albumin (SA)–IL-4 fusion protein leads to higher efficacy in preventing disease development than the administration of wild-type IL-4 or of the clinically approved drug fingolimod. We also show that the SA–IL-4 fusion protein prevents immune-cell infiltration in the spinal cord, decreases integrin expression in antigen-specific CD4+ T cells, increases the number of granulocyte-like myeloid-derived suppressor cells (and their expression of programmed-death-ligand-1) in spinal cord-draining lymph nodes and decreases the number of T helper 17 cells, a pathogenic cell population in EAE. In mice with chronic EAE, SA–IL-4 inhibits immune-cell infiltration into the spinal cord and completely abrogates immune responses to myelin antigen in the spleen. The SA–IL-4 fusion protein may be prophylactically and therapeutically advantageous in the treatment of multiple sclerosis. The enhanced accumulation and residence time of systemically administered interleukin-4 fused to serum albumin in lymph nodes and in the spleen prevents the development of multiple sclerosis in mice.
科研通智能强力驱动
Strongly Powered by AbleSci AI